Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autonomic Manifestations of Testosterone Deficiency in Men

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02715713
Recruitment Status : Withdrawn (Principal Investigator left the institution in August, 2016;)
First Posted : March 22, 2016
Last Update Posted : October 18, 2016
Sponsor:
Information provided by (Responsible Party):
Texas Tech University Health Sciences Center

Tracking Information
First Submitted Date March 17, 2016
First Posted Date March 22, 2016
Last Update Posted Date October 18, 2016
Study Start Date March 2016
Actual Primary Completion Date August 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: March 21, 2016)
Number of patients with testosterone deficiency who will have abnormal autonomic function test (abnormal heart rate response to deep breathing, abnormal Valsalva ratio, and abnormal tilt table i.e. orthostatic hypotension). [ Time Frame: 24 months ]
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: March 21, 2016)
Number of patients with testosterone deficiency and abnormal autonomic function test who will have such abnormalities corrected if they receive testosterone replacement therapy as part of standard of care. [ Time Frame: 24 months ]
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Autonomic Manifestations of Testosterone Deficiency in Men
Official Title Autonomic Manifestations of Testosterone Deficiency in Men
Brief Summary The primary goal of this pilot study is to investigate the association between testosterone deficiency and the presence of abnormalities in the function of the autonomic nervous system. If such association exists, then we will investigate the effect of testosterone replacement therapy on correcting these abnormalities.
Detailed Description

The investigators will recruit 40 men between the ages of 40 to 80-years-old with low testosterone. Participants will be selected among those males referred to the Texas Tech University Health Sciences Center's (TTUHSC's) Internal Medicine Endocrinology Division outpatient clinic for the study and management of testosterone deficiency and to the TTUHSC Urology Department for diagnosis and management of prostate cancer that will result in testosterone deficiency due to surgical or pharmacological castration.

After recruitment, patients will have an initial standard clinical visit where aspects such as fatigue and anxiety will be investigated, followed by a full battery of autonomic testing (tilt table, heart rate response to deep breathing, Valsalva, and the Quantitative Sudomotor Axon Reflex Test (QSART).

Those patients with an initial diagnosis of testosterone deficiency will be initiated on testosterone replacement (intramuscular or skin routes) as standard of care, followed by a second visit in three (3) months--after normalization of serum testosterone levels--to evaluate changes in anxiety and fatigue level, and to repeat the cardiovascular autonomic function test.

Those patients with primary diagnosis of prostate cancer and normal serum testosterone levels will be evaluated a second time after confirmation of low testosterone, as described above. Standard questionnaires will be used to evaluate fatigue and anxiety. The autonomic testing of the heart will include tilt table (tilt the patient 70 degree by special designed table) and heart rate response to deep breathing, and Valsalva maneuver. Descriptive statistics will be compared between before and after treatment using different statistical methods.

Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population

Two groups will be recruited with 20 men in each group:

Group 1 will include 20 men between the ages of 40 to 80-years-old with symptoms and biochemical parameters of low testosterone.

Group 2 will include 20 men between the ages of 40 to 80-years-old with prostate cancer and normal serum testosterone that will be treated with surgical or pharmacological castration, as following standard of care at Urology Division, resulting in testosterone deficiency.

Condition
  • Autonomic Neuropathy
  • Male Hypogonadism
Intervention Not Provided
Study Groups/Cohorts
  • testosterone deficiency group
    Men between the ages of 40 to 80-years-old with testosterone deficiency
  • prostate cancer group
    Men between the ages of 40 to 80-years-old with prostate cancer that will result in testosterone deficiency due to surgical or pharmacological castration.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Withdrawn
Actual Enrollment
 (submitted: October 14, 2016)
0
Original Estimated Enrollment
 (submitted: March 21, 2016)
40
Actual Study Completion Date August 2016
Actual Primary Completion Date August 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria for first group:

  1. Patients with testosterone deficiency (total testosterone< 277 ng/dL [9.6 nmol/L]) measured between 7-10 am, and with one or more symptoms and signs suggestive of androgen deficiency as mainly determined by history.

    • Reduced sexual desire (libido)
    • Decreased spontaneous erections
    • Breast discomfort, gynecomastia
    • Loss of body (axillary and pubic) hair - reduced shaving
    • Very small (<5ml) or shrinking testes
    • Height loss
    • Low trauma fracture
    • Low bone mineral density
    • Hot flushes
    • Sweats
    • Decreased energy
    • Decreased motivation
    • Decreased initiative
    • Decreased self confidence
    • Feeling sad or blue
    • Depressed mood
    • Dysthymia
    • Poor concentration
    • Poor memory
    • Sleep disturbance
    • Increased sleepiness
  2. Age 40 to 80 years

Inclusion Criteria for second group:

  1. Patients who underwent chemical or surgical castration for prostatic cancer who are going to receive androgen deprivation therapy.
  2. Age 40 to 80 years

Exclusion Criteria (both groups):

1. Patients with history or current diagnosis of:

  • Atrial fibrillation.
  • Cardiac arrythmia
  • Pacemaker placement.
  • Myocardial infarction < 3 months
  • Uncontrolled diabetes mellitus with hemoglobin A1c > 8.5% in the last 6 months.
  • Diabetes mellitus with autonomic neuropathy
  • Breast cancer
  • Heart failure with left ventricular ejection fraction below 35%.
  • Severe sleep apnea.
  • Recent eye surgery (< 3 months)
  • Recent ischemic stroke (< 3 months)
  • History of retinal detachment.
  • History of brain aneurysm.
  • Severe chronic obstructive pulmonary disease (COPD) on oxygen therapy.
  • Intraocular hemorrhage and lens dislocation.
  • Glaucoma.
  • Thyroid disease.
  • Not literate in English

Exclusion Criteria for patient who will receive testosterone treatment

  • Metastatic prostate cancer
  • Prostate-specific antigen (PSA) concentration >4.0 mcg/L,
  • Prostate-specific antigen (PSA) >3.0 mcg/L in high-risk men (African-Americans or men with first-degree relatives with prostate cancer). (Measured at clinic visit 1)
  • Polycythemia (hemoglobin level >18 g/dL, hematocrit > 52%) (measured at clinic visit 1)
  • Severe acne.
  • History of venous or arterial thrombosis.
  • Persons not literate in English
Sex/Gender
Sexes Eligible for Study: Male
Ages 40 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT02715713
Other Study ID Numbers L16-059
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD: Undecided
Responsible Party Texas Tech University Health Sciences Center
Study Sponsor Texas Tech University Health Sciences Center
Collaborators Not Provided
Investigators
Principal Investigator: Ahmed M Eldokla, MD Texas Tech Universty Health Science Center
PRS Account Texas Tech University Health Sciences Center
Verification Date October 2016